Abstract
Idarubicin is one of the most recently introduced agents which has gained increasing interest andd is beginning to be widely administered both for the first and second line treatment of AML as well as in breast cancer [1, 2]. In order to provide the basis for its clinical use the pharmacokinetics of this agent have been the topic of many investigations [3–5]. This paper gives an overview of the available literature on the pharmacokinetics of idarubicin and its main metabolite idarubicinol after intravenous and oral administration and demonstrates the results from our own pharmacokinetic studies on the pharmacokinetics of idarubicin after repeated oral administration. In order to obtain an overwiew of the pharmacokinetics of idarubicin the following key determinants must be evaluated.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Robert J, Rigal-Huguet F, Harousseau JL, Pris J, Huet S, Reiffers J, Hurtelopu P, Tamassia V (1987) Pharmacokinetics of Idarubicin after daily intravenous administration in leukemic patients. Leuk Res 11: 961–964
Elbaek K, Ebbehoej E, Jakobsen A, Juul P, Rasmusen S, Bastholt L, Dalmark M. Steiness E (1989) Pharmacokinetics of oral Idarubicin in breast cancer patients with reference to antitumor activity and side effects. Clin Pharmacol Ther 5: 627–634
Broggini M, Sommacampagna B, Paolini A, Ersilia D, Grazia D (1986) Comparative metabolism of daunorubicin and 4-demethosydaunorubicin in mice and rabbits. Cancer Treat Rep 6: 697–702
Zhini G,Vicario GP, Lazzati M, Armacone F (1986) Disposition and metabolism of (14-C) 4-demethoxydaunorubicin HCL (Idarubicin) and (14-C) daunorubicin HCL in the rat. Cancer Chemother Pharmacol 16: 107–115
Tamassia V, Pacciarini MA, Moro E, Piazza E,Vago G, Libretti A (1987) Pharmacokinetic study of intravenous and oral Idarubicin in cancer patients. Int J Clin Pharmacol Res 5: 419–426
Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G (1977) Modellentwicklung in der Pharmakokinetik. Drug Res 27: 904–911
Smith DB, Margison JM, Lucas SB, Wilkinson PM, Howel A (1987) Clinical pharmacology of oral and intravenous 4-demethosydaunorubicin. Cancer Chemother Pharmacol 19: 138–142
Speth P, van de Loo F, Linssen P, Wessels H, Haanen C (1986) Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunorubicin. Clin Pharmacol Ther 12: 643–649
Pannuti F. Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Pacciarini MA (1986) Low dose oral administration of 4-demethoxydaunorubicin ( Idarubicin) in advanced cancer patients. Cancer Chemother Pharmacol 16: 295–299
Lu K, Savaraj N, Kavanagh L, Feun LG, Burgess M, Bodey GP, Loo TL (1986) Cancer Chemother Pharmacol 17: 143–148
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schleyer, E., Budeus, S., Reinhardt, J., Rolff, C., Büchner, T., Hiddemann, W. (1992). Idarubicin Pharmacokinetics. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_105
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_105
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive